734 related articles for article (PubMed ID: 30085422)
1. Analysis of KRAS, NRAS, BRAF, and PIK3CA mutations could predict metastases in colorectal cancer: A preliminary study.
Wojas-Krawczyk K; Kalinka-Warzocha E; Reszka K; Nicoś M; Szumiło J; Mańdziuk S; Szczepaniak K; Kupnicka D; Lewandowski R; Milanowski J; Krawczyk P
Adv Clin Exp Med; 2019 Jan; 28(1):67-73. PubMed ID: 30085422
[TBL] [Abstract][Full Text] [Related]
2. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
[TBL] [Abstract][Full Text] [Related]
3. Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine.
Shen Y; Wang J; Han X; Yang H; Wang S; Lin D; Shi Y
PLoS One; 2013; 8(12):e81628. PubMed ID: 24339949
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.
Palomba G; Doneddu V; Cossu A; Paliogiannis P; Manca A; Casula M; Colombino M; Lanzillo A; Defraia E; Pazzola A; Sanna G; Putzu C; Ortu S; Scartozzi M; Ionta MT; Baldino G; Sarobba G; Capelli F; Sedda T; Virdis L; Barca M; Gramignano G; Budroni M; Tanda F; Palmieri G
J Transl Med; 2016 Oct; 14(1):292. PubMed ID: 27737711
[TBL] [Abstract][Full Text] [Related]
5. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
[TBL] [Abstract][Full Text] [Related]
6. A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer.
Kawazoe A; Shitara K; Fukuoka S; Kuboki Y; Bando H; Okamoto W; Kojima T; Fuse N; Yamanaka T; Doi T; Ohtsu A; Yoshino T
BMC Cancer; 2015 Apr; 15():258. PubMed ID: 25886136
[TBL] [Abstract][Full Text] [Related]
7. Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases.
Zhang J; Zheng J; Yang Y; Lu J; Gao J; Lu T; Sun J; Jiang H; Zhu Y; Zheng Y; Liang Z; Liu T
Sci Rep; 2015 Dec; 5():18678. PubMed ID: 26691448
[TBL] [Abstract][Full Text] [Related]
8. [Combined detection of KRAS, NRAS, BRAF and PIK3CA mutations in the plasma and tumor tissues of colorectal cancer patients].
Liu XN; Tian Z; Wei XF; Wang Q; Zhang JX; Jin MS; Duan XM
Zhonghua Bing Li Xue Za Zhi; 2019 May; 48(5):373-377. PubMed ID: 31104677
[No Abstract] [Full Text] [Related]
9. Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.
Normanno N; Rachiglio AM; Lambiase M; Martinelli E; Fenizia F; Esposito C; Roma C; Troiani T; Rizzi D; Tatangelo F; Botti G; Maiello E; Colucci G; Ciardiello F;
Ann Oncol; 2015 Aug; 26(8):1710-4. PubMed ID: 25851630
[TBL] [Abstract][Full Text] [Related]
10. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
Nam SK; Yun S; Koh J; Kwak Y; Seo AN; Park KU; Kim DW; Kang SB; Kim WH; Lee HS
PLoS One; 2016; 11(3):e0151865. PubMed ID: 26991109
[TBL] [Abstract][Full Text] [Related]
11. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
De Roock W; Claes B; Bernasconi D; De Schutter J; Biesmans B; Fountzilas G; Kalogeras KT; Kotoula V; Papamichael D; Laurent-Puig P; Penault-Llorca F; Rougier P; Vincenzi B; Santini D; Tonini G; Cappuzzo F; Frattini M; Molinari F; Saletti P; De Dosso S; Martini M; Bardelli A; Siena S; Sartore-Bianchi A; Tabernero J; Macarulla T; Di Fiore F; Gangloff AO; Ciardiello F; Pfeiffer P; Qvortrup C; Hansen TP; Van Cutsem E; Piessevaux H; Lambrechts D; Delorenzi M; Tejpar S
Lancet Oncol; 2010 Aug; 11(8):753-62. PubMed ID: 20619739
[TBL] [Abstract][Full Text] [Related]
12. Analysis of KRAS, NRAS, PIK3CA, and BRAF mutational profile in poorly differentiated clusters of KRAS-mutated colon cancer.
Reggiani Bonetti L; Barresi V; Bettelli S; Caprera C; Manfredini S; Maiorana A
Hum Pathol; 2017 Apr; 62():91-98. PubMed ID: 28025078
[TBL] [Abstract][Full Text] [Related]
13. [Analysis of influencing factors of KRAS/NRAS/BRAF/PIK3CA gene mutation consistency in patients with advanced colorectal cancer].
Jiang HQ; Wang BL; Guo W
Zhonghua Yi Xue Za Zhi; 2021 Feb; 101(6):400-404. PubMed ID: 33611888
[No Abstract] [Full Text] [Related]
14. EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.
Ålgars A; Sundström J; Lintunen M; Jokilehto T; Kytölä S; Kaare M; Vainionpää R; Orpana A; Österlund P; Ristimäki A; Carpen O; Ristamäki R
Int J Cancer; 2017 Feb; 140(4):922-929. PubMed ID: 27879995
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial.
Santos C; Azuara D; Viéitez JM; Páez D; Falcó E; Élez E; López-López C; Valladares M; Robles-Díaz L; García-Alfonso P; Bugés C; Durán G; Salud A; Navarro V; Capellá G; Aranda E; Salazar R
Ann Oncol; 2019 May; 30(5):796-803. PubMed ID: 30840064
[TBL] [Abstract][Full Text] [Related]
16. KRAS, NRAS, BRAF, PIK3CA, and AKT1 signatures in colorectal cancer patients in south-eastern Romania.
Brinzan CS; Aschie M; Cozaru GC; Deacu M; Dumitru E; Burlacu I; Mitroi A
Medicine (Baltimore); 2022 Oct; 101(40):e30979. PubMed ID: 36221415
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.
Jauhri M; Bhatnagar A; Gupta S; Bp M; Minhas S; Shokeen Y; Aggarwal S
Tumour Biol; 2017 Feb; 39(2):1010428317692265. PubMed ID: 28222664
[TBL] [Abstract][Full Text] [Related]
18. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
Nakayama I; Shinozaki E; Matsushima T; Wakatsuki T; Ogura M; Ichimura T; Ozaka M; Takahari D; Suenaga M; Chin K; Mizunuma N; Yamaguchi K
BMC Cancer; 2017 Jan; 17(1):38. PubMed ID: 28068936
[TBL] [Abstract][Full Text] [Related]
19. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.
Janku F; Lee JJ; Tsimberidou AM; Hong DS; Naing A; Falchook GS; Fu S; Luthra R; Garrido-Laguna I; Kurzrock R
PLoS One; 2011; 6(7):e22769. PubMed ID: 21829508
[TBL] [Abstract][Full Text] [Related]
20. KRAS, NRAS, BRAF, and PIK3CA mutation rates, clinicopathological association, and their prognostic value in Iranian colorectal cancer patients.
Mirzapoor Abbasabadi Z; Hamedi Asl D; Rahmani B; Shahbadori R; Karami S; Peymani A; Taghizadeh S; Samiee Rad F
J Clin Lab Anal; 2023 Mar; 37(5):e24868. PubMed ID: 36930789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]